Tenofovir alafenamide

Drug Profile

Tenofovir alafenamide

Alternative Names: GS-7340; GS-7340-02; GS-7340-03; TAF; Tenofovir alafenamide fumarate; Vemlidy

Latest Information Update: 09 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Gilead Sciences
  • Developer Gilead Sciences; University Hospital Inselspital
  • Class Antiretrovirals; Purines; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B
  • Phase III HIV-1 infections
  • Phase II HIV infections

Most Recent Events

  • 09 Aug 2017 Launched for Hepatitis B (Treatment-naive, Treatment-experienced) in USA before August 2017 (PO)
  • 29 Jun 2017 Gilead Sciences initiates enrolment in a phase II trial for Hepatitis B (Treatment-experienced) in USA (PO, Tablet) (NCT03180619)
  • 19 Jun 2017 Registered for Hepatitis B (Treatment-naive, Treatment-experienced) in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top